Role of heparin in the antithrombotic treatment of valvulopathies.
Heparin is indicated to replace warfarin in patients with valve disease requiring antithrombotic treatment. Its use in thus necessary for short periods during which warfarin is contraindicated, but the thromboembolic risk persists. These circumstances, which are common in patients with mechanical prostheses, include: hemorrhagic risk or event complicating an existing thromboembolic risk (heart or extracardiac surgery, severe hemorrhage, end of pregnancy); when an unstable situation develops and imposes the rapid diminution or interruption of anticoagulants (stroke, infectious endocarditis); when immediate efficacy is required, rather than the delayed action of warfarin (onset of atrial fibrillation); and when warfarin is contraindicated (early pregnancy). Regardless of whether unfractionated or low molecular-weight heparin (LMWH) is used, therapeutic doses must be prescribed: continuously perfused intravenous and subcutaneous injections (t.i.d.) with repeated biological monitoring for the former, or subcutaneous injections (b.i.d.) with initial biological controls preferred and repeated in elderly subjects or those suffering from renal insufficiency. International guidelines have specified the respective roles of heparin in general, and each preparation individually with an ever-increasing use of LMWH, the efficacy of which has been proven in the majority of common thromboembolic pathologies and in pregnant women.